Leerink Partnrs Issues Negative Outlook for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB) – Leerink Partnrs reduced their FY2025 EPS estimates for Biogen in a research note issued on Thursday, October 30th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of $14.85 for the year, down from their prior estimate of $15.60. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. Biogen’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS.

Several other research analysts have also commented on BIIB. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, September 24th. Mizuho lifted their price objective on shares of Biogen from $169.00 to $177.00 and gave the stock an “outperform” rating in a research note on Monday. Truist Financial started coverage on shares of Biogen in a research note on Monday, July 21st. They set a “hold” rating and a $142.00 target price for the company. Sanford C. Bernstein boosted their target price on shares of Biogen from $155.00 to $157.00 and gave the company a “market perform” rating in a research note on Monday. Finally, Wall Street Zen lowered shares of Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Nine research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and a consensus target price of $176.42.

Biogen Stock Down 1.4%

NASDAQ BIIB opened at $149.33 on Monday. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The company has a fifty day moving average of $144.77 and a two-hundred day moving average of $134.22. The firm has a market capitalization of $21.89 billion, a price-to-earnings ratio of 14.28, a PEG ratio of 1.17 and a beta of 0.13. Biogen has a 52 week low of $110.04 and a 52 week high of $179.20.

Hedge Funds Weigh In On Biogen

A number of large investors have recently added to or reduced their stakes in BIIB. Elevation Point Wealth Partners LLC bought a new position in Biogen in the second quarter worth about $25,000. Vision Financial Markets LLC bought a new position in Biogen in the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. bought a new position in Biogen in the first quarter worth about $27,000. Rothschild Investment LLC raised its holdings in Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares in the last quarter. Finally, Zions Bancorporation National Association UT bought a new position in Biogen in the first quarter worth about $29,000. 87.93% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 517 shares of Biogen stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the sale, the insider directly owned 5,772 shares in the company, valued at $770,850.60. The trade was a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.18% of the stock is owned by insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.